Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $25.00 price target on the stock.
Separately, Piper Sandler reduced their price objective on Milestone Pharmaceuticals from $6.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, March 5th.
View Our Latest Stock Report on MIST
Milestone Pharmaceuticals Stock Performance
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.05. As a group, sell-side analysts anticipate that Milestone Pharmaceuticals will post -0.79 EPS for the current year.
Institutional Trading of Milestone Pharmaceuticals
An institutional investor recently raised its position in Milestone Pharmaceuticals stock. BNP Paribas Financial Markets lifted its stake in Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Free Report) by 177.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,900 shares of the company’s stock after buying an additional 10,800 shares during the period. BNP Paribas Financial Markets’ holdings in Milestone Pharmaceuticals were worth $30,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 86.18% of the company’s stock.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
Read More
- Five stocks we like better than Milestone Pharmaceuticals
- How to Calculate Stock Profit
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- 5 Top Rated Dividend Stocks to Consider
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- What Do S&P 500 Stocks Tell Investors About the Market?
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.